StockData

BGM vs Zhengye Biotechnology

BGM and ZYBT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BGM and ZYBT compare

BGM grew revenue faster over the last twelve months (51.1% versus −37.6% for Zhengye Biotechnology).

BGM keeps more of each dollar of sales as profit, with a net margin of −52.6% compared with −60.0% at Zhengye Biotechnology.

BGM scores higher on the StockData Score (9 against 4 for Zhengye Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBGMZYBT
Size and price
Share price$8.01$1.43
Change, 1 year−97.1%−33.5%
Change, 5 years−98.3%–
Beta (5Y)1.940.41
Employees20651
StockData Score
Total score9 (better)4
Valuation score00
Growth score2 (better)0
Performance score2 (better)1
Health score5 (better)3
Dividend score00
Growth
Revenue growth (TTM)51.1% (better)−37.6%
Revenue growth, 5Y average−5.4%–
Net income growth (TTM)–−717%
Profitability
Gross margin16.6%20.5% (better)
Operating margin−33.2% (better)−60.6%
Net margin−52.6% (better)−60.0%
FCF margin−10.4%10.6% (better)
Return on equity−9.2% (better)−26.1%
Return on invested capital−4.8% (better)−18.1%
Financial health
Debt / equity0.000.26 (better)
Interest coverage–−20.7×
Current ratio1.24 (better)1.14
Piotroski F-score4 (better)3
Ownership
Held by institutions0.00%–
Held by insiders52.5%90.7%
Short interest, % of float0.00%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.